Company: HCWB
Filing Date: 2025-05-23
Form Type: 8-K
Source: 0000950170-25-076994
Chunk: 0

Company: HCW Biologics Inc.
Filing Date: 2025-05-23
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

As reported in our Current Report on Form 8-K filed on May 15, 2025, HCW Biologics Inc. (the “ Company”) entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd. (“ Armistice”) on May 13, 2025 that included a grant of pre-funded warrants to purchase up to 513,140 shares of the Company’s common stock $0.0001 per share (“ Common Stock”) that may be exercised at any time at an exercise price of $0.0001 per share (the “ Pre-Funded Warrants”). As reported in our Current Report on Form 8-K filed on May 20, 2025, on May 15, 2025, the Company issued 177,140 shares of Common Stock to Armistice as a result of the exercise of some of the Pre-Funded Warrants. On May 21, 2025, Armistice delivered its notice to exercise some of its Pre-Funded Warrants by delivering a notice of exercise to the Company and paying the exercise price. The Company issued 126,000 shares of registered Common Stock to Armistice on May 22, 2025. As of May 22, 2025, Armistice retains Pre-Funded Warrants to purchase up to 210,000 shares of Common Stock.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                        HCW BIOLOGICS INC.                   
  Date:      May 23, 2025      By:      /s/ Hing C. Wong                     
                                        Founder and Chief Executive Officer